A Clinical Study Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma.
Beijing Bio-Targeting Therapeutics Technology Co., Ltd
Beijing Bio-Targeting Therapeutics Technology Co., Ltd
Beijing Neurosurgical Institute
Duke University
Biogen